Elanco Animal Health (ELAN)
8.71
0.09 (1.04%)
At close: Apr 14, 2025, 3:46 PM
1.04% (1D)
| Bid | 8.65 |
| Market Cap | 4.32B |
| Revenue (ttm) | 4.44B |
| Net Income (ttm) | 338M |
| EPS (ttm) | 0.68 |
| PE Ratio (ttm) | 12.8 |
| Forward PE | 13.43 |
| Analyst | Hold |
| Ask | 8.71 |
| Volume | 3,481,809 |
| Avg. Volume (20D) | 5,030,844 |
| Open | 8.82 |
| Previous Close | 8.62 |
| Day's Range | 8.48 - 8.85 |
| 52-Week Range | 8.03 - 18.80 |
| Beta | 1.44 |
About ELAN
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indicati...
Sector Healthcare
IPO Date Sep 20, 2018
Employees 9,000
Stock Exchange NYSE
Ticker Symbol ELAN
Website https://www.elanco.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ELAN stock is "Hold." The 12-month stock price forecast is $13.5, which is an increase of 55.08% from the latest price.
Stock ForecastsNext Earnings Release
Elanco Animal Health is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+12.75%
Elanco Animal Health shares are trading higher aft...
Unlock content with
Pro Subscription
6 months ago
-0.75%
Elanco shares are trading higher after the company received FDA approval for Credelio Quattro broad-spectrum canine oral parasiticide in a monthly dose.
